Publications by authors named "Konstantinos Tsafis"
Mediterr J Rheumatol
March 2024
Article Synopsis
- The JAK/STAT pathway plays a key role in various rheumatic diseases, leading to the development of JAK inhibitors for treatment, particularly in rheumatoid arthritis (RA).
- Filgotinib is a selective JAK1 inhibitor authorized for RA and ulcerative colitis, showing promising efficacy in clinical trials involving both treatment-naïve and experienced patients.
- Long-term studies indicate filgotinib improves disease activity and quality of life in RA, demonstrating non-inferiority to adalimumab, but also highlight potential risks for infectious side effects, excluding herpes zoster, which is infrequent.
